NCT05678010View on ClinicalTrials.gov

A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

May 17, 2023

Primary Completion Date

May 17, 2028

Study Completion Date

May 17, 2028

Conditions
Solid TumorMetastatic Solid TumorSolid CarcinomaSolid Tumor, AdultMetastatic TumorMetastatic Cancer
Interventions
DRUG

AZD1390

Dose level 1: 20 Dose level 2: 40 Dose level 3: 60 Dose level 4: 80

RADIATION

Stereotactic Body Radiotherapy

Participants will receive Stereotactic Body Radiotherapy/SBRT to 2 sites of metastatic tumors consecutively. The two treatment sites will be randomized to SBRT to one site and SBRT + AZD1390 to the other site. Both sites will receive 30Gy in 5 fractions.

Trial Locations (5)

10065

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison

11725

Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities), Commack

98109

University of Washington (Data Collection AND Data Analysis), Seattle

07748

Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER